FDA allows sample pool COVID-19 testing to Quest Diagnostics
The United States Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to Quest Diagnostics, allowing it to conduct sample pooling, and test up to four swab samples for COVID-19 at the same time, the clinical laboratory wrote in a statement on Saturday.
This method of testing could potentially save both time and resources as it runs samples taken from four people at the same time, using additional supplies only if the result comes back positive, the statement read.
“This EUA for sample pooling is an important step forward in getting more COVID-19 tests to more Americans more quickly while preserving testing supplies,” said FDA Commissioner Stephen Hahn.
Get involved!
Comments